On Oct. 3, 2018, Scripps Research announced that Calibr scientitsts from Scripp’s drug development division had begun using ReFRAME, to identify existing drugs that show promise for treating major diseases.

Two FDA-approved drugs were already being tested in clinical trials-one as a treatment for tuberculosis and another for the parasite Cryptosporidium spp., a major cause of severe diarrhea-within only a few short years of Calibr scientists discovering their utility.

By 2020, the collection had grown to comprise over 14,000 compounds, including drugs that are already being repurposed for a number of diseases.